TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8390548
Drug: Monovalent B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent B vaccine of the same dose (10(4) TCID50)
Study: 8390548
Drug: Trivalent vaccine
Normalized name: Fluzone 2024-2025 trivalent vaccine Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent vaccine containing 10(6) TCID50 of B
Study: 3102348
Drug: Penicillin (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (4.8 MIU aqueous procaine penicillin G plus 1 g oral probenecid)
Study: 3102348
Drug: Tetracycline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (1.5 g followed by 500 mg four times daily for four days)
Study: 28859868
Drug: 20% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% human albumin solution (HAS) infusion
Study: 22484118
Drug: 5-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day concomitant therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice daily, tinidazole 500 mg twice daily)
Study: 22484118
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily for 5 days followed by esomeprazole 40 mg twice daily, levofloxacin 500 mg twice daily, tinidazole 500 mg twice daily for 5 more days)
Study: 22484118
Drug: 5-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day concomitant therapy
Study: 20025055
Drug: AAE581 (balicatib)
Normalized name: Balicatib
DrugBank: Balicatib (DB12239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAE581 (balicatib) at 0, 5, 10, 25, or 50 mg/D during 1 year
Study: 17721910
Drug: Cognitive-behavioural body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural body image therapy (BIT)
Study: 16446313
Drug: Irbesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (angiotensin II receptor blocker) for 4 months
Study: 15061232
Drug: Tray-based 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tray-based 10% carbamide peroxide/dentifrice/mouth rinse combination system
Study: 11326145
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (3 g intravenous infusion)
Study: 11326145
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (100 ml x 0.9% saline, placebo)
Study: 8840615
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (omeprazole 20 mg OD, bismuth subcitrate, amoxycillin)
Study: 8840615
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (bismuth subcitrate 120 mg QID, amoxycillin 500 mg QID, metronidazole 400 mg TID for 2 weeks)
Study: 1623756
Drug: Optimal Treatment
Normalized name: Optimal-D3
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal Treatment (OT)
Study: 1623756
Drug: Normal Treatment
Normalized name: Normaloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Treatment (NT)
Study: 1623756
Drug: Normal Treatment
Normalized name: Normaloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Treatment (NT) less than 4.5 L/min/m2
Study: 1623756
Drug: Optimal Treatment
Normalized name: Optimal-D3
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal Treatment (OT) greater than 4.5 L/min/m2
Study: 6595350
Drug: Intrathecal (IT)
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal (IT) methotrexate plus intravenous intermediate dose methotrexate
Study: 30298556
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg oral capsule once daily before bedtime for 2 months)
Study: 24962875
Drug: Synbiotic (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic (1 billion CFU of Lactobacillus casei, L. rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, L. acidophilus, B. infantis, L. bulgaricus and fructooligosacharide)
Study: 21186921
Drug: Silver acetate
Normalized name: SILVER ACETATE
DrugBank: Silver (DB12965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver acetate solution
Study: 17420902
Drug: rHuEpo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo (400 U/kg, subcutaneously twice a week)
Study: 12909068
Drug: Early angiography
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early angiography without tirofiban pre‐treatment
Study: 12909068
Drug: Delayed angiography
Normalized name: FAST-PAK ANGIOGRAPHY KIT WITH VASCORAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed angiography after 24‐48h pre‐treatment with tirofiban
Study: 8807065
Drug: Simultaneous resistance
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous resistance to more than one antibiotic by E. coli isolates
Study: 8807065
Drug: Colonization by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonization by Klebsiella species and Shigella species resistant to antibiotics
Study: 1863002
Drug: Three-way system
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-way system including hydrophilic polymer-coated catheter, daily catheter care, and disinfection with povidone-iodine
Study: 6821866
Drug: Surgical excision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical excision or biopsy followed by local radiotherapy and randomization to chemotherapy regimens (protocol IESS 7299)
Study: 6821866
Drug: Protocol IESS
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol IESS 7450 (radiotherapy to all areas of known disease and four drug chemotherapy)
Study: 27368672
Drug: Single-dose tenapanor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose tenapanor 180 mg
Study: 27368672
Drug: Repeated-dose tenapanor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated-dose tenapanor 15, 30, 60, or 90 mg twice daily for 7 days
Study: 27128839
Drug: Crushed rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Crushed rivaroxaban tablet in applesauce suspension (Crushed‐Oral)
Study: 27128839
Drug: Crushed rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Crushed rivaroxaban tablet in water suspension via NG tube (Crushed‐NG)
Study: 27128839
Drug: Whole rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Whole rivaroxaban tablet (Reference [Whole‐Oral])
Study: 23094903
Drug: Euglycemic control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemic control (80‐140 mg/dL)
Study: 23094903
Drug: Conventional approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional approach (180‐200 mg/dL)
Study: 19713801
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for 30 minutes on 3 consecutive days
Study: 17240225
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (n = 74)
Study: 30095360
Drug: Blood cardioplegia
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood cardioplegia (St. Thomas' Harefield preparation)
Study: 22820210
Drug: Topical cooling
Normalized name: Castiva Cooling Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cooling
Study: 30095360
Drug: Induction and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and maintenance dosing
Study: 30095360
Drug: Re-dosing interval
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-dosing interval
Study: 19034332
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day (ATV)
Study: 19034332
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day + Amlodipine 20 mg/day (ATV+AML)
Study: 8882962
Drug: P-VEBEC regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-VEBEC regimen (epirubicin 50 mg/sqm, cyclophosphamide 300 mg/sqm, etoposide 100 mg/sqm on weeks 1, 3, 5, 7; vinblastine 5 mg/sqm and bleomycin 5 mg/sqm on weeks 2, 4, 6, 8; prednisone 50 mg/sqm/day for the first two weeks and then every other day) with rG-CSF 5 micrograms/Kg/day for 4 consecutive days starting on day 2 of every week.
Study: 1563574
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg promegestone
Study: 1563574
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg promegestone
Study: 1563574
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lynestrenol
Study: 21853612
Drug: Infusion solution
Normalized name: Albumin Human/Dextran 40/Sodium Chloride 8%-6.8%-0.9% Intravenous Solution [OMISIRGE INFUSION SOLUTION]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion solution 'potassium and magnesium asparginate' at a rate of 1.5-2 ml/kg/h (n = 44)
Study: 21853612
Drug: Magnesium free
Normalized name: magnesium oxide Oral Tablet [Phillips' Cramp-free]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium free crystalloid solutions (n = 33)
Study: 18174969
Drug: Grazax (Timothy-grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazax (Timothy-grass pollen extract) administered sublingually
Study: 16948861
Drug: Cissus quadrangularis
Normalized name: Cissus quadrangularis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cissus quadrangularis formulation (two daily doses)
Study: 16948861
Drug: Cissus quadrangularis
Normalized name: Cissus quadrangularis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cissus quadrangularis formulation with diet (2100‐2200 calories/day)
Study: 16948861
Drug: Cissus quadrangularis
Normalized name: Cissus quadrangularis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cissus quadrangularis formulation without diet
Study: 16948861
Drug: Cissus quadrangularis
Normalized name: Cissus quadrangularis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cissus quadrangularis formulation (no diet)
Study: 10583024
Drug: Risedronate administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate administered 2 h after dinner
Study: 10583024
Drug: Risedronate administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate administered 1 h before a meal
Study: 10583024
Drug: Risedronate administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate administered 0.5 h before a meal
Study: 10583024
Drug: Risedronate administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate administered 4 h before a meal
Study: 1819621
Drug: Aztreonam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (1 g intravenously or intramuscularly, twice daily)
Study: 1819621
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 g intravenously or intramuscularly, twice daily)
Study: 1819621
Drug: Amikacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (500 mg intravenously or intramuscularly, twice daily)
Study: 6291832
Drug: MK 421
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK 421 (10 mg p.o.)
Study: 28581397
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by concurrent chemo-IMRT
Study: 28581397
Drug: Concurrent chemo-IMRT
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo-IMRT alone
Study: 9892313
Drug: Intramuscular flunitrazepam
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular flunitrazepam (1 mg i.m.)
Study: 9892313
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol (5 mg i.m.)
Study: 8694035
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (micronized estradiol, 2 mg/day)
Study: 26504795
Drug: HCARE (high-concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCARE (high-concentration ashwagandha root extract) 300mg twice daily for 8 weeks
Study: 26504795
Drug: Placebo (starch)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch) 300mg twice daily for 8 weeks
Study: 22768174
Drug: Valsartan (VAL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (VAL, 320 mg/d)
Study: 19180484
Drug: Chondroitins 4
Normalized name: chondroitin 4-sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitins 4 and 6 sulfate (CS) 800 mg once daily for 2 years
Study: 17410467
Drug: Rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (100 mg t.i.d.) with ibuprofen (1800 mg/day)
Study: 17410467
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with ibuprofen (1800 mg/day)
Study: 23450051
Drug: Hydrocortisone therapy
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone therapy
Study: 11490212
Drug: Intraurethral PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraurethral PGE2 gel (1 mg)
Study: 11490212
Drug: Intracavernous papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous papaverine (60 mg)
Study: 11767426
Drug: Hydroxyzine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 100 mg
Study: 11767426
Drug: Hydroxyzine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 100 mg and cimetidine 400 mg
Study: 11767426
Drug: Hydroxyzine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 100 mg and effervescent cimetidine (cimetidine 200 mg + sodium citrate 1.8 g)
Study: 11767426
Drug: Effervescent cimetidine
Normalized name: cimetidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent cimetidine orally in 30 ml of water 5 min before anaesthetic induction
Study: 11767426
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Hydroxyzine 100 mg)
Study: 11767426
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Hydroxyzine 100 mg and cimetidine 400 mg)
Study: 11767426
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Hydroxyzine 100 mg and effervescent cimetidine)
Study: 3440226
Drug: Prochlorperazine 10
Normalized name: prochlorperazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 10 mg
Study: 3440226
Drug: Prochlorperazine 20
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prochlorperazine 20 mg
Study: 3440226
Drug: Prochlorperazine 30
Normalized name: prochlorperazine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 30 mg
Study: 3440226
Drug: Prochlorperazine 40
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prochlorperazine 40 mg
Study: 3440226
Drug: Prochlorperazine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (30 mg or 40 mg)
Study: 3440226
Drug: Prochlorperazine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (all doses)
Study: 3440226
Drug: Prochlorperazine (higher-than-conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (higher-than-conventional doses)
Study: 18728643
Drug: Docetaxel-cisplatin (D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel-cisplatin (D 60 mg m(‐2) and P 80 mg m(‐2) on day 1, every 3-4 weeks)
Study: 18728643
Drug: Docetaxel monotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel monotherapy (D 70 mg m(‐2), every 3 weeks)
Study: 16760295
Drug: FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI plus celecoxib 400 mg twice daily for 14 days (arm B)
Study: 12648175
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 50 micro g of intravaginal misoprostol
Study: 12648175
Drug: Two consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two consecutive doses of intravaginal 50 micro g misoprostol 6 h apart
Study: 11526759
Drug: Monitored methods
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monitored methods of treatment (group C)
Study: 3798264
Drug: Midazolam (Dormicum;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (Dormicum; Roche) 0.1 mg/kg
Study: 19583930
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine combined with Songling Xuemaikang Capsule (SXC)
Study: 19583930
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine combined with SXC
Study: 17113893
Drug: Oxybutynin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin (2.5 mg three times per day)
Study: 9764338
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment with DEC (6 mg/kg) and ivermectin (200 micrograms/kg)
Study: 9764338
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment with DEC (6 mg/kg) and ivermectin (400 micrograms/kg)
Study: 9764338
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with ivermectin (200 micrograms/kg) followed by DEC (6 mg/kg) after 5 days
Study: 8311599
Drug: Laxative, nonpulsatile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative, nonpulsatile perfusion
Study: 8311599
Drug: Laxative, pulsatile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative, pulsatile perfusion
Study: 8311599
Drug: No laxative,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No laxative, nonpulsatile perfusion
Study: 8311599
Drug: No laxative,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No laxative, pulsatile perfusion
Study: 3414920
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 600 mg orally one hour before surgery
Study: 3414920
Drug: Tubocurarine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine 0.05 mg/kg before induction of anaesthesia
Study: 999409
Drug: Chlorpromazine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (12.5 mg/70 kg, i.m.)
Study: 999409
Drug: Chlorpromazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (25 mg/70 kg, i.m.)
Study: 999409
Drug: Chlordiazepoxide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (25 mg/70 kg, i.m.)
Study: 999409
Drug: Chlordiazepoxide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (50 mg/70 kg, i.m.)
Study: 999409
Drug: Morphine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (15 mg/70 kg, i.m.)
Study: 999409
Drug: Morphine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (30 mg/70 kg, i.m.)
Study: 31574878
Drug: Intravenous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous granisetron 3 mg every 8 hours for 4 days or until ICU discharge
Study: 27789297
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa treatment
Study: 21787825
Drug: Intranasal Shigella
Normalized name: Shigella dysenteriae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Shigella flexneri 2a Invaplex 50 vaccine via Dolphin™ device at 240, 480, and 690 μg doses
Study: 21787825
Drug: Intranasal Shigella
Normalized name: Shigella dysenteriae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Shigella flexneri 2a Invaplex 50 vaccine via Dolphin™ device
Study: 21787825
Drug: Intranasal Shigella
Normalized name: Shigella dysenteriae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Shigella flexneri 2a Invaplex 50 vaccine via pipette at 240 μg dose
Study: 14718713
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of 1-octanol
Study: 8299318
Drug: 349U85 hydrochloride
Normalized name: terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 349U85 hydrochloride (doses from 2 mg to 250 mg)
Study: 2847994
Drug: Oral delta‐9‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delta‐9‐tetrahydrocannabinol (THC), 15 mg/m2
Study: 2847994
Drug: Prochlorperazine (PCZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (PCZ), 10 mg
Study: 31670603
Drug: Naringenin 150
Normalized name: NARINGENIN
DrugBank: Naringenin (DB03467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naringenin 150 mg from an extract of whole oranges standardized to 28% naringenin, taken three times/day for 8 weeks
Study: 31301434
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and irrigation with CUR solution (100 mg/L)
Study: 31301434
Drug: SRP, irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP, irrigation with CUR solution (100 mg/L), and LED irradiation (465-485 nm, 60 s)
Study: 26615377
Drug: Midazolam 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.01 mg/kg/IV and ketamine 1 mg/kg/IV
Study: 11166906
Drug: vCP205 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vCP205 vaccine
Study: 11522187
Drug: vCP205 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vCP205 vaccine with SF-2 rgp120
Study: 9573498
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with lisinopril
Study: 9573498
Drug: Low-dose therapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose therapy with lisinopril
Study: 9573498
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use variation
Study: 3408038
Drug: Diltiazem (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (loading dose 0.5 mg.kg‐1 followed by infusion of 5 micrograms.kg‐1.min‐1)